Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Christian Lienhardt Discusses the Newly Launched TB-PACTS Database

Christian Lienhardt

  Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinical trial data from Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases [...]

A Slight Chemical Alteration Makes a TB Drug More Effective

Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against [...]

23 Nov 2015
by Working Group

Posted in Announcements

2015 WGND Annual Meeting and Reception

Cape Town, South Africa, Dec. 5, 17:30 – 20:30 We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2015 at Southern Sun Cape Sun Hotel, Cape Town, South Africa, on Saturday, Dec. 5th from 17:30 to 20:30. This meeting is held before the 46th Union World Conference on [...]

TB Alliance Drug,TBA-354, enters Phase I Clinical Trials


TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009

2014 Report on Tuberculosis Research Funding Trends, 2005–2013


Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).

22 Sep 2014

2014 WGND Annual Meeting, Barcelona, Oct. 29, 15h-19h


We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.

9 Sep 2014
by Working Group

Posted in Announcements, Events, TB Treatment, Uncategorized

Results of Phase III ReMoxTB Clinical Trial Published


Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]

11 Jun 2014
by Working Group

Posted in Action, Announcements, TB News, Uncategorized

Panel of TB experts releases report calling for the prioritization of tuberculosis R&D


The Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States government to combat the disease.

Kick TB Campaign Expands to Brazil


The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of the 2014 World Cup.

Delamanid approved for use in the European Union


The European Commission has approved delaminid (Deltyba) for use in patients suffering from MDR-TB.